FDA Approves Relugolix for Advanced Prostate Cancer

On December 18, 2020, the U.S. Food and Drug Administration (FDA) approved relugolix for the treatment of adult patients with advanced prostate cancer. It is the first and only oral gonadotropin-releasing hormone receptor antagonist for men with advanced prostate cancer.

Read the FDA announcement.

Read Myovant Sciences' announcement.

Posted 12/21/2020